Remove Big Data Remove Clinical Trials Remove Medicine Remove Pharma Companies
article thumbnail

AI continues to gain momentum in the biopharmaceutical industry in 2023

Pharmaceutical Technology

The report also suggested that Big Data was thought to be the most important partner to AI, in terms of introducing technology-related changes in the pharmaceutical sector (Figure 2). In addition to collaborating with AI-technology providers, pharma companies are also engaging in vertical integration.

Big Data 303
article thumbnail

What’s the next step in big data and AI?

Drug Discovery World

Big data and AI are all the rage. But, beyond these buzzwords and the quantity of data, what’s next for these powerful tools? Troy Groetken says that data has the ability to create personalised, predictive and preventative medicine tailored to individual patients and identified patient groups/populations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. David Clifton is professor of clinical machine learning in the Department of Engineering Science of the University of Oxford.

article thumbnail

EMA pilot will see if clinical trial data should be digested ‘raw’

pharmaphorum

A pilot study has been launched by the EMA to see whether it is helpful for regulators to look at the ‘raw data’ from clinical trials submitted in support of new marketing application along with the usual structured analyses from sponsors.

article thumbnail

The DDW Podcast: 2023 in review

Drug Discovery World

Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. Listen here. Listen here. Listen here.

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost.

article thumbnail

How digital innovation is helping therapeutics to get to market faster

Drug Discovery World

As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Relation Therapeutics, which uses high-resolution biology, ML and clinical insights to discover transformational medicines.